Background
==========

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the synovial joints. Immunologic dysfunction results in the hypertrophy of the synovial tissue, causing erosion of the articular cartilage and subchondral bone \[[@B1]\]. The involvement of the cervical spine is common in RA patients, with a reported prevalence of up to 86% \[[@B2]\]. The majority of RA patients with radiological abnormalities of the cervical spine remain asymptomatic for years \[[@B3]\]. Only a small fraction of patients eventually require surgical treatment, primarily due to neurological deterioration. For those who need surgical intervention, early surgical intervention is desirable \[[@B2],[@B4]\]. If there is a delay in surgical intervention, it can lead to a poor outcome and even death \[[@B5],[@B6]\]. Neurological improvement can be seen after surgery; in one study, patients with RA and patients with osteoarthritis had similarly high proportions of good global scores and satisfaction with their treatment after surgery \[[@B7]\]. However, it remains unclear whether RA patients undergoing cervical spine surgery differ from those who do not receive surgical treatment in terms of their clinical characteristics and the disease activity of RA. A previous cohort study showed a correlation between the severity of the RA activity in the peripheral joints and the progression of cervical spine instability \[[@B8]\]. However, few studies using a large observational database have examined this issue.

The aim of this study was to examine the clinical characteristics of RA patients who underwent cervical spine surgery using a multicenter observational database. Our hypothesis is that RA patients requiring cervical spine surgery have a higher disease activity than those who do not undergo surgical treatment.

Methods
=======

Data source
-----------

The National Database of Rheumatic Diseases by iR-net in Japan (NinJa) is a nationwide, multicenter (40 centers), observational cohort database of patients with rheumatic diseases established in 2002 in Japan \[[@B9]\]. The collected data consist of two components: patient information over the course of the year \[outcome, death, hospitalization, operations, number of total joint arthroplasty procedures in large joints (hip, knee, shoulder, elbow), malignancy and tuberculosis\] and information collected on each day that the patient visits the outpatient department of each center \[tender-joint count (TJC) and swollen-joint count (SJC), modified health assessment questionnaire (MHAQ) score, Steinbrocker functional classification (class), patient global and pain visual analog scale scores (PtGVAS, PtPainVAS), the doctor VAS (DrGVAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, disease activity score (DAS) 28-CRP and the use of corticosteroids, methotrexate (MTX) or biologics\].

Patients
--------

The data of RA patients who were enrolled in the fiscal years from 2003 to 2011 were employed for the analysis (the fiscal year was defined as April to March, because official schedule tends to be run according to the fiscal year in Japan). The data acquired from 2002 was eliminated because of the incompleteness of data. All patients fulfilled the 1987 classification criteria of the American College of Rheumatology. After simple comparison of the demographic data year by year, the patients who underwent cervical spine surgery (excluding those who underwent cervical spine surgery for non-RA-related causes) and whose data were available for two consecutive years were chosen as cases. The total number of cases included was 39.

The background data of the cases were extracted from the fiscal year before surgery to represent the preoperative status. We first simply compared the background data of the patients between the cases and total patients enrolled in the same fiscal year. Then, eligible controls (1:3 pair matching) were selected, which were defined as patients enrolled in the same fiscal year as the case subjects, who were matched for age (within ±1 year), gender and disease duration (within ±1 year). The total number of controls was 106. Some cases did not have three controls. The background data of the cases in the previous year of surgery and the controls were compared. The examined factors were the stage, class, MHAQ, CRP, ESR, PtPainVAS, PtGVAS, DrGVAS, DAS28-CRP, number of arthroplasty procedures, tender-joint count and the use of steroids, MTX or biologics.

The NinJa project was reviewed and approved by the National Hospital Organization research ethics committees, and this study protocol was approved by the research ethics committees of the Sagamihara National Hospital and the University of Tokyo Hospital, and all enrolled patients provided their written informed consent.

Analyses and statistics
-----------------------

The JMP 11.0.0 software program (SAS, Cary, NC) was used for the statistical analysis. Descriptive statistics were used to analyze the clinical information, demographic factors and other test data. Continuous variables were expressed as the medians and interquartile ranges (IQR). Yearly trends were analyzed by a single regression model or chi-square test, or by the Tukey-Kramer method. Differences between groups were examined using the Mann--Whitney U test for continuous variables or the chi-square test for categorical data, when appropriate. A p-value \<0.05 was considered to indicate a significant difference.

Results
=======

Table [1](#T1){ref-type="table"} shows the demographic and disease characteristics of the patients included in the NinJa Database. There were no significant yearly differences in gender (chi-square test). However, the age was significantly older in 2010 (p \< 0.01, Tukey-Kramer method) and the disease duration was significantly shorter in fiscal year 2007 (p \< 0.01, Tukey-Kramer method) (Table [1](#T1){ref-type="table"}). The proportion of patients using corticosteroids decreased from 2003 to 2011, whereas the proportion using MTX and biologics linearly increased during this period (coefficient: 2.43, p \< 0.01 for MTX, coefficient 2.76, p \< 0.01 for biologics, single regression model) (Table [1](#T1){ref-type="table"}). We also counted the number of patients who underwent cervical spine surgery or total joint replacement and those with RA recruited in this database in each fiscal year. The annual incidence of cervical spine surgery was approximately 0.17%, and remained relatively stable during the study period, whereas that of total joint replacement showed a slightly decreasing trend (coefficient -0.21, p \< 0.01 for total knee replacement, coefficient -0.05, p \< 0.01 single regression model) (Table [1](#T1){ref-type="table"}).

###### 

Demographic and desease characteristics of the patients included in NinJa database

  **Fiscal year**                       **2003**     **2004**     **2005**     **2006**     **2007**     **2008**     **2009**     **2010**     **2011**     **p-value**   **Coefficient**
  ------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------- -----------------
  Total number of registered patients   4100         3994         4650         5152         5463         6502         7179         7254         10368                       
  Age (years) (IQR)                     62(55--69)   63(55--70)   64(56--71)   63(56--71)   64(56--71)   64(56--71)   64(56--72)   65(57--72)   65(56--72)   \<0.0001       
  Gender (female:male)                  3410:700     3313:681     3832:818     4229:923     4448:1015    5346:1156    5895:1284    5921:1333    8375:1993    0.7341         
  Disease dutaion (years) (IQR)         11(5--20)    11(5--19)    10(5--19)    10(5--19)    9(4--19)     10(5--19)    10(5--19)    10(5--19)    9(4--18)     0.0020         
  Use of MTX (%)                        36           48           53           53           47           51           64           58           60           0.0084        2.43
  Use of corticosteroid (%)             64           63           62           63           61           58           53           53           49           0.0002        -1.88
  Use of biologics (%)                  0.4          2.1          4.3          9            12           14           20           19           20           \<0.0001      2.76
  Cervical spine surgery (cases) (%)    8 (0.19)     7 (0.17)     4 (0.08)     6 (0.12)     8 (0.15)     10 (0.15)    10 (0.14)    15 (0.21)    30 (0.29)    0.1593        0.01
  Total knee replacement (cases) (%)    146 (3.55)   121 (3.02)   117 (2.52)   130 (2.52)   132 (2.42)   118 (1.81)   156 (2.17)   133 (1.87)   158 (1.52)   0.0002        -0.21
  Total hip replacement (cases) (%)     33 (0.80)    37 (0.93)    50 (1.08)    48 (0.93)    45 (0.82)    51 (0.78)    46 (0.64)    43 (0.59)    56 (0.54)    0.0098        -0.05

The data are represented as the medians (IQR). The yearly differences were analyzed by the Tukey-Kramer method.

Yearly trends were analyzed by a single regression model, and are expressed by coefficients and p-values.

Fusion surgery was the most frequently performed surgery (29 cases, 74.4%), followed by laminoplasty (four cases, 10.25%), laminectomy (two cases, 5.1%) and unspecified surgery (four cases, 10.25%).

Table [2](#T2){ref-type="table"} summarizes the patient characteristics, which compared the cases and total patients enrolled in the same fiscal year. The data showed that the cases tended to be more functionally disabled (e.g. MHAQ, PtGVAS) and to have a more severe RA status (e.g. number of arthroplastic surgeries, tender joint count, swollen joint count, CRP, ESR, DAS28-CRP) and to have a longer disease duration. However, RA is known to be progressive disease, and there was a possibility that a longer disease duration could have influenced the other parameters (function, RA severity). Therefore, we decided to compare the characteristics of the patients using a case-matched study, as described in the Methods.

###### 

Summary of patient characteristics

  **Fiscal year**                     **2004**      **2005**              **2006**      **2007**              **2008**      **2009**              **2010**                                                                                                      
  ------------------------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ------ ----------------- ----------------- ---------------- ----------------- -----------------
  Age (years) (IQR)                 58.5(55.5-72)   63(55--70)           65(62--76)     63(55--70)           60(59--76)     63(56--71)           61(59--63)     64(56--71)          64   64(56--71)           63(58--74)     64(56--72)          65(57--70)     65(57--72)
  Gender (female:male)                   3:1        3313:681                 2:1        3832:818                 3:0        4229:923                 2:0        4448:1015          1:0   5346:1156               11:2        5895:1284              13:0        5921:1333
  Disease dutaion (years) (IQR)        6(4--9)      11(5--19)            15(12--36)     10(5--19)            13(11--30)     10( 5--19)          23.5(15--32)    9(4--19)            24   10(5--19)            16(12--20)     10(5--19)           20(15--40)     10(5--19)
  Arthroplastic surgery (IQR)          0(0--0)      0(0--0)                1(0--2)      0(0--0)                1(0--4)      0(0--0)                2(0--3)      0(0--0)             0%   0(0--0)                0(0--3)      0(0--0)               0(0--1)      0(0--0)
  Tender joint count (IQR)            9(1--30)      3(1--6)              15(13--16)     3(1--6)                1(0--4)      2(1--6)               19(4--34)     2(0--5)             4    2(0--5)                3(1--9)      2(0--4)               2(1--4)      1(0--3)
  Swollen joint count (IQR)           2(0--10)      2(0--5)                0(0--4)      2(0--5)                0(0--2)      1(0--4)                3(3--3)      1(0--3)             3    1(0--4)                2(0--6)      1(0--3)               2(0--5)      1(0--3)
  MHAQ (IQR)                       1.4(0.35-1.48)   0.5(0--1)           2.3(1.3-2.9)    0.4(0--1)            1.5(0.88-2)    0.4(0--1)           1.55(1--2.1)    0.4(0--1)          1.25  0.38(0--1)          1(0.69-1.44)    0.25(0--0.9)       1(0.26-1.94)    0.25(0--0.9)
  CRP (mg/dl) (IQR)                 3.4(0.9-4.2)    0.59(0.18-1.7)     2.7(1.75-3.35)   0.55(0.18-1.57)    0.47(0.05-0.71)  0.47(0.18-1.4)     1.26(1.02-1.5)   0.41(0.17-1.22)    1.95  0.31(0.13-1.03)    1.04(0.18-2.78)  0.28(0.11-0.9)     2.0(0.14-3.5)   0.26(0.1-0.76)
  ESR (mm/h) (IQR)                  38.5(14--66)    37(20--60)           43(17--77)     35(19--56)            23(9--46)     33(18--55)          74.5(46--103)   31(16--51)          51   29(15--49)         37.5(29--71.3)   28(14--47)        55.5(5.5-84.8)   25(13--45)
  DAS28-CRP (IQR)                  4.15(3.15-6.11)  3.34(2.45-4.25)    4.71(4.67-5.38)  3.35(2.43-4.24)    2.98(1.13-3.61)  3.14(2.29-4.06)    4.93(3.46-6.39)  2.99(2.12-3.89)    4.19  2.85(2.04-3.75)    3.32(2.58-4.46)  2.72(1.94-3.6)    3.39(2.3-4.78)   2.55(1.83-3.46)
  Stage1 (%)                              0         14.5                      0         15                        0         15.9                      0         17.7                0    16.6                     8.3        18                      7.7        19.6
  Stage2 (%)                             100        25                      33.3        25.2                      0         25                        0         25.7                0    25.6                      0         27.2                     0         26.5
  Stage3 (%)                              0         21                      33.3        20.3                      0         19.9                     50         20.4                0    20.7                     25         19.3                   15.4        19.6
  Stage4 (%)                              0         39.5                    33.3        39.5                     100        39.2                     50         36.2               100   37.1                    66.7        35.5                   76.9        34.3
  Class1 (%)                              0         25                        0         26.2                      0         26.2                      0         26.9                0    25.3                     25         26                       0         28.2
  Class2 (%)                             75         52.7                      0         53.4                    33.3        53.3                      0         52.9                0    52                       50         53.9                   61.5        52.6
  Class3 (%)                             25         19.1                    66.7        17.4                    66.7        17.4                     100        17.5                0    19.3                     25         16.8                   38.5        16.4
  Class4 (%)                              0         3.2                     33.3        3                         0         3.1                       0         2.7                100   3.4                       0         3.3                      0         2.8
  PtPainVAS (IQR)                   5.5(2.3-7.0)    3.3(1.6-5.5)          6.1(4--7)     3.1(1.5-5.3)        5.5(1.6-6.8)    3(1.4-5.2)          5.5(2.5-8.5)    3(1.3-5.1)         4.3   2.6(1.1-5)          3.4(1.4-8.3)    2.6(1.1-5)        2.25(0.98-4.95)  2.4(1--4.8)
  PtGVAS (IQR)                       5.7(3--8.4)    3.5(1.7-5.5)        6.8(2.3-8.1)    3.4(1.6-5.3)        5.9(0.2-7.8)    3.2(1.5-5.2)        5.5(2.5-8.5)    3(1.4-5.1)         5.3   2.8(1.2-5)         4.7(0.85-7.75)   2.7(1.2-5)         3.1(1.85-5.9)   1.6(0.7-2.9)
  DrGVAS (IQR)                       7(3.4-8.3)     2.5(1.3-4.1)         5.2(3.1-7)     2.4(1.1-4)          0.7(0.5-3.4)    2(1--3.5)            6.15(3.3-9)    1.8(0.9-3.1)       2.6   1.6(0.6-3)          3.8(0.8-4.8)    1.8(0.8-3)         2.5(1.05-4.4)   0.25(0--0.88)
  Use of MTX (%)                         33         48                        0         53                       100        53.9                     50         47.3                0    51.1                    53.8        64.3                     0         58.2
  Use of corticosteroid (%)              100        63                       100        62                       100        64                       100        61                 100   59.1                     100        53                     84.6        53.4
  Use of biologics (%)                    0         2.1                       0         4.3                       0         9                         0         11.7                0    13.6                    38.5        20                       0         18.6

VAS: visual analog scale, MHAQ: Modified Health Assessment Questionnaire, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, DAS28: Disease Activity Score of 28 Joints, MTX: Methotrexate.

A comparison of the cases and total number of patients enrolled in the same fiscal year. The data are presented as the medians (IQR).

Table [3](#T3){ref-type="table"} summarizes the patient characteristics according to whether they underwent cervical spine surgery. The patients who underwent cervical spine surgery were more likely to have more tender joints (3 vs. 1, p \< 0.01). They also exhibited significantly higher MHAQ scores (1.13 vs. 0.5, p \< 0.01), higher DAS28-CRP values (3.63 vs. 2.81, p \< 0.01), a higher PtGVAS (4.9 vs. 2.9, p \< 0.05) and a higher DrGVAS (3.4 vs. 1.6, p \< 0.05). They also tended to be in higher Steinbrocker functional classification (p \< 0.05). Regarding the treatment of RA, the use of MTX was significantly lower in cases (13% vs. 40%, p \< 0.01), and use of corticosteroids was significantly higher in cases (90% vs. 60%, p \< 0.01) than controls. The use of biologics was not significantly different between cases and controls.

###### 

Comparison of the background data of the cases and controls

                                  **Cases**         **Controls**        **p value**
  ------------------------------- ----------------- ----------------- -------------
  Age (years) (IQR)               63(59--73)        63(59--69)               0.7224
  Gender (female:male)            35:4              99:7                     0.4614
  Disease dutaion (years) (IQR)   15(12--30)        15(11--22)                 0.52
  Arthroplastic surgery (%)       41                31                       0.1527
  Tender joint count (IQR)        3(1--10)          1(0--4)                  0.0087
  Swollen joint count (IQR)       2(0--4)           1(0--3)                  0.1389
  MHAQ (IQR)                      1.13(0.75-1.88)   0.5(0.1-1)               0.0001
  CRP (mg/dl) (IQR)               1.5(0.26-3.05)    0.36(0.13-1.06)          0.0023
  ESR (mm/h) (IQR)                46(21--70)        33(20.5-57.5)            0.1948
  DAS28-CRP (IQR)                 3.63(2.60-4.68)   2.81(2.01-3.43)          0.0012
  Stage1 (%)                      5.3               6.5                            
  Stage2 (%)                      13.2              19.6                           
  Stage3 (%)                      18.4              19.6                           
  Stage4 (%)                      63.1              54.3                     0.7823
  Class1 (%)                      7.9               20.4                           
  Class2 (%)                      47.3              58.1                           
  Class3 (%)                      39.5              18.3                           
  Class4 (%)                      5.3               3.2                      0.0395
  PtPainVAS (IQR)                 3.9(1.8-6.4)      3(1.2-5)                 0.0937
  PtGVAS (IQR)                    4.9(2--6.8)       2.9(1.2-5)               0.0314
  DrGVAS (IQR)                    3.4(1.4-5.1)      1.6(1--3.1)              0.0121
  Use of MTX (%)                  13                40                       0.0022
  Use of corticosteroid (%)       90                60                       0.0007
  Use of biologics (%)            10                8                        0.7414

The data are presented as the median (IQR). P values were calculated using the chi-square test for gender, Steinbrocker functional class and stage and arthroplastic surgery. The Mann--Whitney U test was used for the other items.

Discussion
==========

In this retrospective analysis using a large database, we found that only a small fraction (1.7/1,000/year) of patients underwent cervical spine surgery. However, despite the increasing use of biologics, the incidence of cervical spine surgery remained unchanged over recent years. Our data also showed that patients undergoing cervical spine surgery had a higher disease activity and exhibited a more severe degree of functional disability than those who did not undergo cervical spine surgery.

Although radiographic abnormalities of the cervical spine are frequently seen in RA patients \[[@B2]\], our study showed that only a small fraction (1.7/1,000/year) of patients had a history of cervical spine surgery. A previous study showed that the number of RA-related cervical spinal surgeries in 609 RA patients was 0.2%, which was similar to our data \[[@B10]\]. There was a stark discrepancy between the high prevalence of radiographic abnormalities and the relative rarity of cervical spine surgery. There are several possible explanations for this discrepancy. One is that the prognosis of RA patients with cervical lesions is generally favorable. For example, a previous report showed that there was cervical spine involvement in up to 86% of RA patients, but only 10% of these patients actually developed neurological deterioration \[[@B11]\]. However, it is also possible that some patients were underdiagnosed, presumably due to the involvement of multiple joints.

The annual incidence of cervical spine surgery did not change much during recent years according to the NinJa database. The increased use of biologics has reportedly led to a reduction in the number of RA-related arthroplasty procedures, such as total hip replacements \[[@B12]\]. Our data agreed with this previous study, showing a decrease in the number of total joint replacement surgeries; however, the number of cervical spine surgeries did not exhibit a substantial decrease. We hypothesize that the protective effects of biologics on the cervical spine are limited. In line with this view, a prior study showed that the use of biologics prevented the development of de novo cervical spine lesions in RA patients, but failed to inhibit the progression of preexisting RA lesions \[[@B13]\]. Regarding the use of MTX, our data showed that the use of MTX was significantly lower in cases than controls. Another previous study showed that the use of MTX did not improve the cervical spine instability \[[@B14]\], so our results are reasonable. On the contrary, the use of corticosteroids was significantly higher in cases than in controls. A previous study showed that the administration of a higher dose of corticosteroid was a significant general factor predicting the development of myelopathy \[[@B15]\], supporting our present findings.

We also found that patients undergoing cervical spine surgery had a high disease activity despite receiving intensive treatment for RA, including biologics. There was a previous study that showed a correlation between the progression of peripheral erosive disease and the severity of cervical subluxation \[[@B16]\]. Our data further supported that study by using a case-matched method. Some previous reports recommended early prophylactic surgical intervention for cervical instability in RA patients \[[@B17]-[@B19]\]. Regardless whether surgery is undertaken, patients with a high disease activity should be closely monitored for neurological deterioration.

Interestingly, there were no significant differences in the pain scores between those with and without a history of cervical spine surgery. Therefore, physicians should pay close attention to not only the patient's pain, but also the neurological status and function of patients who do not report high pain levels.

There are several possible limitations associated with this study. First, we were unable to conduct a multivariate analysis because the number of patients who underwent cervical spine surgery was too small. In addition, we were unable to obtain detailed information on the type of spinal lesions (e.g. atlantoaxial subluxation) and the surgical procedures. We also could not count the number of cases with cervical involvement because we did not take plain radiographs of the cervical spine in every patient. Therefore, we could not determine how many of the RA patients in the NinJa database had cervical involvement. Finally, the institutions participating in the NinJa database are mostly national hospitals, which may limit the generalizability of our findings. In addition, our research period was relatively short, so our results regarding the effects of biologics on the cervical spine may change in the future as more patients are treated using these agents.

Conclusions
===========

Our findings revealed that RA patients requiring cervical spine surgery tend to have a higher disease activity than control subjects. Our results also indicate that conducting a meticulous evaluation of cervical lesions is therefore required, particularly in patients with a high disease activity in spite of the intensive use of biologics.
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